Palatin Technologies filings document regulatory disclosures for a biopharmaceutical company developing melanocortin receptor-targeted drug candidates. Its 8-K reports and proxy materials cover capital-structure actions, including a 1-for-50 reverse stock split, warrant-share issuance approvals, equity incentive plan matters and listing or trading-status notices for the company’s common stock.
The filing record also includes material-event disclosure on a research collaboration, license and patent assignment agreement with Boehringer Ingelheim for retinal disease programs, annual meeting voting results, advisory executive-compensation votes, corporate governance matters, operating and financial results, and clinical or regulatory disclosures tied to Palatin’s development pipeline.
Palatin Technologies (PTN) is prioritizing MC4R agonists for obesity. It plans a Phase 1 study of its long-acting peptide in the first half of calendar 2027; for its oral small molecule, it plans IND-enabling work in the first half and a Phase 1 study in the second half of 2027. Both programs focus on rare neuroendocrine diseases and MC4R pathway disorders.
Boehringer Ingelheim paid €2.0 million ($2.3 million) upfront in August 2025 and €5.5 million ($6.5 million) after a September 2025 research milestone under a retinal-disease agreement; the agreement provides for up to €280,000,000 (approximately $328,000,000) in contingent milestones, plus royalties. Altanispac received exclusive rights to PL9643 for dry eye disease, and Palatin recognized $3,751,122 in fiscal 2026 license revenue through non-cash debt cancellation. A Phase 2 bremelanotide-tirzepatide study reported 4.4% weight reduction versus 1.6% for placebo over eight weeks.
At June 30, 2026, Palatin had $7.5 million in cash and cash equivalents and $1.8 million in current liabilities. The company concluded that substantial doubt existed about its ability to continue as a going concern for one year from the financial statements’ issuance date and said it needs additional funding for development and clinical trials.
AuGC BioFund LP, together with AuGC Partners LLC and Evan Markegard, reports beneficial ownership of 84,000 shares of Palatin Technologies Inc. common stock, representing 4.7% of the class. The group has shared voting and dispositive power over 84,000 shares and no sole voting or dispositive power. The percentage is based on 1,779,275 shares outstanding as of May 12, 2026, as reported by Palatin. AuGC Partners LLC and Mr. Markegard may be deemed beneficial owners through their advisory and control roles but expressly disclaim beneficial ownership under Rule 13d-4. The position is reported as ownership of 5 percent or less of the outstanding common stock.
Palatin Technologies director Arlene Morris received a grant of stock options covering 2,400 shares of common stock with an exercise price of $7.70 per share. The options vest 50% on August 3, 2027 and 50% on August 3, 2028, and expire on August 3, 2037. After this award, she directly holds 3,497 stock options. The grant was approved by the Compensation Committee under Palatin’s 2011 Stock Incentive Plan and is reported under a Rule 10b5-1 trading arrangement.
DUNTON ALAN W reported acquisition or exercise transactions in this Form 4 filing.
PALATIN TECHNOLOGIES INC director Alan W. Dunton was granted 2,200 stock options under the 2011 Stock Incentive Plan, exercisable at $7.70 per share and granted on August 3, 2026. The options vest 50% on August 3, 2027 and 50% on August 3, 2028, and expire on August 3, 2037.
After this grant, Dunton holds 25,769 derivative securities tied to Palatin common stock. The grant is affirmed as made under a Rule 10b5-1 trading plan.
PALATIN TECHNOLOGIES INC director John K A Prendergast reported receiving a stock option covering 2,900 shares of common stock at an exercise price of $7.70 per share under the 2011 Stock Incentive Plan. The option vests 50% on August 3, 2027 and 50% on August 3, 2028, and expires on August 3, 2037, leaving him with stock options over 26,921 shares in total.
Palatin Technologies, Inc. held its annual meeting of stockholders on July 28, 2026, where four proposals were presented: election of directors, ratification of the independent registered public accounting firm for the fiscal year ending June 30, 2026, an amendment to the 2011 Stock Incentive Plan to increase shares available for equity awards by 260,000 shares, and an advisory vote on executive compensation for the fiscal year ended June 30, 2025.
As of the June 22, 2026 record date, there were 1,842,625 votes entitled to be cast, including 1,779,275 common shares, 4,030 shares of Series A Preferred Stock (1,534 votes), and 3,400 shares of Series D Preferred Stock (61,816 votes). A total of 1,000,506 votes, or 54.3% of votes entitled, were present in person or by proxy. Director nominees received between 337,172 and 654,056 votes for, with 319,687 broker non-votes each. The auditor ratification proposal received 982,584 for, 15,833 against, and 2,089 abstentions; the stock plan amendment received 650,452 for, 28,736 against, 1,630 abstentions, and 319,687 broker non-votes; and the say-on-pay proposal received 649,559 for, 28,732 against, 2,527 abstentions, and 319,687 broker non-votes.
Palatin Technologies President and CEO Carl Spana reported three F-code transactions in common stock dated July 15, 2026. In total, 294 shares were withheld by the issuer at per-share values of $14.34, $11.72 and $11.77 to satisfy employee withholding taxes on recently vested stock grants.
Palatin Technologies Executive VP and CFO/COO Stephen T. Wills reported tax-withholding dispositions totaling 195 shares of common stock on July 15, 2026. The company withheld 94, 79 and 22 shares at per-share values of $14.34, $11.72 and $11.77 to satisfy employee withholding taxes on recently vested equity grants. After these transactions, Wills directly owned 63,792 common shares. The filing affirms these transactions under a Rule 10b5-1 trading plan.
Palatin Technologies is asking stockholders to approve four main items at its fully virtual annual meeting on July 28, 2026. Stockholders will vote on electing four directors, ratifying KPMG as auditor for the year ending June 30, 2026, amending the 2011 Stock Incentive Plan, and an advisory say-on-pay resolution.
The equity plan amendment would add 260,000 shares of common stock to the reserve, bringing total authorized under the plan to 406,000 shares, to continue granting stock options and restricted stock units to employees, directors, and consultants. As of the June 22, 2026 record date, there were 1,779,275 common shares outstanding, with additional voting power from Series A and Series D convertible preferred stock.
The proxy describes how to register, attend, and vote at the virtual-only meeting, details quorum and broker voting rules, and outlines board structure, committee responsibilities, director independence, and director compensation. It also discloses 2024–2025 audit and tax fees paid to KPMG and key terms of the amended equity plan, including minimum vesting periods, change-in-control treatment, overhang metrics, and clawback and detrimental-activity provisions.
Palatin Technologies, Inc. filed a Form 25 notifying the SEC and NYSE American LLC of the removal of its class of securities from listing and registration. The filing certifies compliance with the Exchange rules and 17 CFR 240.12d2-2 procedures. The Form is signed by the company CFO on May 28, 2026.